Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikiProjectMed
Search

Dexamethasone

This article's lead is ready for translation. Click for more information.
From WikiProjectMed
Dexamethasone
Skeletal formula of dexamethasone
Ball-and-stick model of the dexamethasone molecule
Names
Trade namesDextenza, Ozurdex, others
  • (8S,9R,10S,11S,13S,14S,16R,17R)-9-Fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
Clinical data
Pregnancy
category
Routes of
use
By mouth,intravenous therapy (IV),intramuscular injection (IM),subcutaneous injection (IM),intraosseous (IO),eye drop
Defined daily dose1.5 mg[2]
External links
AHFS/Drugs.comSystemic:Monograph
Eye and ear:Monograph
MedlinePlusa682792
Legal
License data
Legal status
Pharmacokinetics
Bioavailability80–90%
Protein binding77%
MetabolismLiver
Eliminationhalf-life190 minutes (3.2 hours)
ExcretionUrine (65%)
Chemical and physical data
FormulaC22H29FO5
Molar mass392.461 g·mol−1
3D model (JSmol)
Melting point262 °C (504 °F)
  • O=C(CO)[C@]3(O)[C@]2(C[C@H](O)[C@]4(F)[C@@]1(C(=CC(=O)C=C1)CC[C@H]4[C@@H]2C[C@H]3C)C)C
  • InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1 checkY
  • Key:UREBDLICKHMUKA-CXSFZGCWSA-N checkY

Dexamethasone is a type ofcorticosteroid medication.[3] It is used in the treatment of many conditions, includingrheumatic problems, a number ofskin diseases, severeallergies,asthma,chronic obstructive lung disease,croup,brain swelling, eye pain followingeye surgery, and along withantibiotics intuberculosis.[3] Inadrenocortical insufficiency, it should be used together with a medication that has greatermineralocorticoid effects such asfludrocortisone.[3] Inpreterm labor, it may be used to improve outcomes in the baby.[3] It may be taken by mouth, as aninjection into a muscle, orintravenously.[3] The effects of dexamethasone are frequently seen within a day and last for about three days.[3]

The long-term use may result inthrush, bone loss,cataracts, easy bruising, or muscle weakness.[3] It has been frequently used by mouth in pregnancy and not been found to cause problems for the baby.[4] It should not be taken whenbreastfeeding.[3] Dexamethasone hasanti-inflammatory andimmunosuppressant effects.[3]

Dexamethasone was first made in 1957 and was approved for medical use in 1961.[5][6] It is on theWorld Health Organization's List of Essential Medicines.[7] Dexamethasone is not expensive.[8] In the United States, a month of medication typically costs less than US$25.[3] In India, a course of treatment for preterm labor costs about US$0.5.[8] It is available in most areas of the world.[8] In 2017, it was the 321st most commonly prescribed medication in the United States, with more than one million prescriptions.[9]

Medical uses

Dexamethasone phosphate injection vials
A single vial of dexamethasone phosphate for injection

Anti-inflammatory

Dexamethasone is used to treat manyinflammatory andautoimmune conditions, such asrheumatoid arthritis andbronchospasm.[10]Idiopathic thrombocytopenic purpura, a decrease in numbers ofplatelets due to an immune problem, responds to 40 mg daily for four days; it may be administered in 14-day cycles. It is unclear whether dexamethasone in this condition is significantly better than other glucocorticoids.[11]

It is also given in small amounts[12] before and/or after some forms ofdental surgery, such as the extraction of thewisdom teeth, an operation which often leaves the patient with puffy, swollen cheeks.

Dexamethasone is commonly given as a treatment forcroup in children, as a single dose can reduce the swelling of the airway to improve breathing and reduce discomfort.[13]

It is injected into the heel when treatingplantar fasciitis, sometimes in conjunction withtriamcinolone acetonide.

It is useful to counteractallergic anaphylactic shock, if given in high doses.

It is present in certaineye drops – particularly aftereye surgery – and as anasal spray, and certain ear drops (can be combined with an antibiotic and an antifungal). Dexamethasone intravitreal steroid implants have been approved by theFDA to treat ocular conditions such asdiabetic macular edema,central retinal vein occlusion, anduveitis.[14] Dexamethasone has also been used with antibiotics to treat acuteendophthalmitis.[15]

Dexamethasone is used in transvenous screw-incardiac pacing leads to minimize the inflammatory response of themyocardium. The steroid is released into the myocardium as soon as the screw is extended and can play a significant role in minimizing the acute pacing threshold due to the reduction of inflammatory response. The typical quantity present in a lead tip is less than 1.0 mg.

Dexamethasone may be administered before antibiotics in cases ofbacterial meningitis. It acts to reduce the inflammatory response of the body to the bacteria killed by the antibiotics (bacterial death releases proinflammatory mediators that can cause a response which is harmful), thus reducing hearing loss and neurological damage.[16]

Cancer

a) Extensive mucosal erythema b) gastric ulcer with bleeding spot at antrum c) 2 weeks of high-dose dexamethasone d) four cycles of high-dose dexamethasone, a healed ulcer scar

People withcancer undergoingchemotherapy are often given dexamethasone to counteract certainside effects of their antitumor treatments. Dexamethasone can increase theantiemetic effect of5-HT3 receptor antagonists, such asondansetron.[17] The exact mechanism of this interaction is not well-defined, but it has been theorized that this effect may be due to, among many other causes, inhibition ofprostaglandin synthesis,anti-inflammatory effects,immunosuppressive effects, decreased release ofendogenousopioids, or a combination of the aforementioned.[18]

Inbrain tumors (primary or metastatic), dexamethasone is used to counteract the development ofedema, which could eventually compress other brain structures. It is also given incord compression, where a tumor is compressing the spinal cord.

Dexamethasone is also used as a direct chemotherapeutic agent in certainhematological malignancies, especially in the treatment ofmultiple myeloma, in which dexamethasone is given alone or in combination with other chemotherapeutic drugs, including most commonly withthalidomide (Thal-dex),lenalidomide,bortezomib (Velcade, Vel-dex),[19] or a combination ofdoxorubicin (Adriamycin) andvincristine orbortezomib/lenalidomide/dexamethasone.

COVID-19

Dexamethasone treatment is recommended by theNational Institutes of Health (NIH) in the US, and by theNational Health Service in the UK, for people with COVID-19 who who requiresupplemental oxygen or are mechanically ventilated.[20][21] Dexamethasone has not been recommended in people with COVID-19 who do not require supplemental oxygen or hospitalization,[20] and the NIH recommends against such use.[21]

TheInfectious Diseases Society of America (IDSA) guideline panel suggests the use of glucocorticoids for patients with severe COVID-19 where severe is defined as patients with SpO2 ≤94% on room air, and those who require supplemental oxygen, mechanical ventilation, or ECMO.[22] The IDSA recommends against the use of glucocorticoids for those with COVID-19 without hypoxemia requiring supplemental oxygen.[22]

Endocrine

Dexamethasone is the treatment for the very rare disorder of glucocorticoid resistance.[23][24]

Inadrenal insufficiency andAddison's disease, dexamethasone is prescribed when the patient does not respond well toprednisone ormethylprednisolone.

It can be used incongenital adrenal hyperplasia in older adolescents and adults to suppress ACTH production. It is typically given at night.[25]

Pregnancy

Dexamethasone may be given to women at risk of delivering prematurely to promotematuration of the fetus' lungs. This administration, given from day to one week before delivery, has been associated withlow birth weight, although not with increased rates of neonatal death.[26]

Dexamethasone has also been used during pregnancy as anoff-label prenatal treatment for the symptoms ofcongenital adrenal hyperplasia (CAH) in female babies. CAH causes a variety of physical abnormalities, notablyambiguous genitalia. Early prenatal CAH treatment has been shown to reduce some CAH symptoms, but it does not treat the underlyingcongenital disorder. This use is controversial: it is inadequately studied, only around one in ten of the fetuses of women treated are at risk of the condition, and serious adverse events have been documented.[27] Experimental use of dexamethasone in pregnancy for fetal CAH treatment was discontinued in Sweden when one in five cases suffered adverse events.[28]

A small clinical trial found long-term effects on verbal working memory among the small group of children treated prenatally, but the small number of test subjects means the study cannot be considered definitive.[29][30]

High-altitude illnesses

Dexamethasone is used in the treatment ofhigh-altitude cerebral edema (HACE), as well ashigh-altitude pulmonary edema (HAPE). It is commonly carried on mountain-climbing expeditions to help climbers deal with complications ofaltitude sickness.[31][32]

Nausea and vomiting

Intravenous dexamethasone is effective for prevention of nausea and vomiting in people who had surgery and whose post-operative pain was treated with long-acting spinal or epidural spinal opioids.[33]

The combination of dexamethasone and a5-HT3 receptor antagonist such asondansetron is more effective than a 5-HT3 receptor antagonist alone in preventing postoperative nausea and vomiting.[34]

Dexamethasone, when used as an anti emetic during surgery, does not appear to increase rates of wound infection and it is unclear if it has an effect on wound healing.[35]

Sore throat

A single dose of dexamethasone or another steroid speeds improvement of asore throat.[36]

Dosage

Thedefined daily dose is 1.5 mg by mouth or by injection.[2] For anaphylaxis in adults typically a one time dose of 10 mg either by mouth or by injection is used.[37] In children the typical dose is typically 0.6 mg/kg.[37]

For inflammatory syndromes as a result of infection 0.5 to 24 mg a day may be used in adults and 0.2 to 0.4 mg/kg in children.[38] To speed the development of a babies lungs 6 mg by injection into a muscle twice per day for two days may be used during pregnancy.[38]

For altitude sickness a dose of 4 mg every 6 hours may be used.[39] Generally this is only needed for a day or two when used together with descending.[39]

The recommended dose for severe COVID19 is 6 mg by mouth or intravenously a day for 7 to 10 days.[40]

Contraindications

Contraindications of dexamethasone include,[41][42] but are not limited to:

Side effects

The exact rates of side effects of dexamethasone are not available, hence estimates have been made as to the incidence of the adverse effects below based on the adverse effects of related corticosteroids and on available documentation on dexamethasone.[42][43][44][45][46]

Common

  • Acne
  • Insomnia
  • Vertigo
  • Increased appetite
  • Weight gain
  • Impaired skin healing
  • Depression
  • Euphoria
  • Hypertension
  • Increased risk of infection
  • Raised intraocular pressure
  • Vomiting
  • Dyspepsia
  • Confusion
  • Amnesia
  • Irritability
  • Nausea
  • Malaise
  • Headaches
  • Cataract (in cases of long-term treatment it occurs in about 10% of patients)

Unknown frequency

Withdrawal

Sudden withdrawal after long-term treatment with corticosteroids can lead to:[42]

Interactions

Known drug interactions include:[42]

Pharmacology

Mechanism of action of dexamethasone in multiple myeloma[47]

As a glucocorticoid, dexamethasone is anagonist of theglucocorticoid receptor (GR). It has minimalmineralocorticoid activity.[48][49][50]

Chemistry

Dexamethasone is asyntheticpregnanecorticosteroid andderivative ofcortisol (hydrocortisone) and is also known as 1-dehydro-9α-fluoro-16α-methylhydrocortisone or as 9α-fluoro-11β,17α,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione.[51][52] Themolecular andcrystal structure of dexamethasone has been determined byX-ray crystallography.[53]

Synthesis

To synthesize dexamethasone, 16β-methylprednisolone acetate isdehydrated to the 9,11-dehydroderivative.[54][55] This is then reacted with a source ofhypobromite, such as basicN-bromosuccinimide, to form the 9α-bromo-11β-hydrin derivative, which is then ring-closed to an epoxide. A ring-opening reaction withhydrogen fluoride intetrahydrofuran gives dexamethasone.[citation needed]

Dexamethasone synthesis

History

Dexamethasone was firstsynthesized in 1957 byPhilip Showalter Hench.[5][56] It was introduced for medical use in 1958.[49]

On 16 June 2020, theRECOVERY Trial announced preliminary results stating that dexamethasone improves survival rates of hospitalized patients withCOVID-19 receiving oxygen or on aventilator. Benefits were only observed in patients requiring respiratory support; those who did not require breathing support saw a worse survival rate than the control group, although the difference may have been due to chance.[57] A preprint containing the full dataset was published on 22 June 2020 and demand for dexamethasone surged after publication of the preprint.[58] The preliminary report was published inThe New England Journal of Medicine on 18 July 2020.[59]

TheWorld Health Organization (WHO) states that dexamethasone should be reserved for seriously ill and critical patients receiving COVID-19 treatment in a hospital setting,[60] and the WHO Director-General stated that "WHO emphasizes that dexamethasone should only be used for patients with severe or critical disease, under close clinical supervision. There is no evidence this drug works for patients with mild disease or as a preventative measure, and it could cause harm."[61] In July 2020, the WHO stated they are in the process of updating treatment guidelines to include dexamethasone or other steroids.[62]

In July 2020, theEuropean Medicines Agency (EMA) started reviewing results from the RECOVERY study arm that involved the use of dexamethasone in the treatment of patients with COVID-19 admitted to the hospital to provide an opinion on the results and in particular the potential use of dexamethasone for the treatment of adults with COVID-19.[63][64]

Society and culture

Cost

Dexamethasone is inexpensive.[8] In the United States a month of medication is typically priced less thanUS$25.[3] In India, a course of treatment for preterm labor is aboutUS$0.50.[8] The drug is available in most areas of the world.[8]

  • Dexamethasone costs (US)
    Dexamethasone costs (US)
  • Dexamethasone prescriptions (US)
    Dexamethasone prescriptions (US)

Route

It may be taken by mouth, as a tablet or elixir, as aninjection into a muscle,intravenously, or via an eye drop.[3]

Nonmedical use

Dexamethasone is given inlegal Bangladesh brothels to prostitutes not yet of legal age, causing weight gain aimed at making them appear older and healthier to customers and police.[65]

Dexamethasone and mostglucocorticoids are banned by sporting bodies including theWorld Anti-Doping Agency.[66]

Veterinary use

Combined withmarbofloxacin andclotrimazole, dexamethasone is available under the name Aurizon,CAS number 115550-35-1, and used to treat difficult ear infections, especially in dogs. It can also be combined withtrichlormethiazide to treat horses with swelling ofdistal limbs and generalbruising.[67]

See also

References

  1. 1.01.1"Dexamethasone Use During Pregnancy".Drugs.com.Archived from the original on 17 May 2016. Retrieved26 July 2024.
  2. 2.02.1"WHOCC - ATC/DDD Index".www.whocc.no.Archived from the original on 22 September 2020. Retrieved1 September 2020.
  3. 3.003.013.023.033.043.053.063.073.083.093.103.11"Dexamethasone". The American Society of Health-System Pharmacists.Archived from the original on 31 August 2017. Retrieved29 July 2015.
  4. "Prescribing medicines in pregnancy database".Australian Government. 3 March 2014.Archived from the original on 8 April 2014. Retrieved22 April 2014.Drugs which have been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the fetus having been observed.
  5. 5.05.1Rankovic, Zoran; Hargreaves, Richard; Bingham, Matilda (2012).Drug discovery and medicinal chemistry for psychiatric disorders. Cambridge: Royal Society of Chemistry. p. 286.ISBN 9781849733656.Archived from the original on 5 March 2016.
  6. Fischer, Jnos; Ganellin, C. Robin (2006).Analogue-based Drug Discovery. John Wiley & Sons. p. 485.ISBN 9783527607495.Archived from the original on 1 August 2020. Retrieved17 June 2020.
  7. World Health Organization (2019).World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization.hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  8. 8.08.18.28.38.48.5"DEXAMETHASONE FOR ACCELERATING LUNG MATURATION IN PRETERM BABIES"(PDF).Archived(PDF) from the original on 22 December 2015. Retrieved29 July 2015.
  9. "Dexamethasone - Drug Usage Statistics".ClinCalc.Archived from the original on 12 April 2020. Retrieved11 April 2020.
  10. Till, John."Paramedic Clinical Training Aid". Archived fromthe original on 31 March 2012. Retrieved30 August 2011.
  11. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. (January 2010)."International consensus report on the investigation and management of primary immune thrombocytopenia".Blood.115 (2):168–86.doi:10.1182/blood-2009-06-225565.PMID 19846889.
  12. Schmelzeisen R, Frölich JC (1993)."Prevention of postoperative swelling and pain by dexamethasone after operative removal of impacted third molar teeth".European Journal of Clinical Pharmacology.44 (3):275–7.doi:10.1007/BF00271371.PMID 8491244.S2CID 12528750.Archived from the original on 24 June 2020. Retrieved17 June 2020.
  13. "Croup- Diagnosis & Treatment".Mayo Clinic.Archived from the original on 10 October 2017. Retrieved13 October 2017.Dexamethasone is usually recommended because of its long-lasting effects (up to 72 hours).
  14. Brady CJ, Villanti AC, Law HA, Rahimy E, Reddy R, Sieving PC, et al. (February 2016)."Corticosteroid implants for chronic non-infectious uveitis".Cochrane Database of Systematic Reviews.2: CD010469.doi:10.1002/14651858.CD010469.pub2.PMC 5038923.PMID 26866343.
  15. Kim CH, Chen MF, Coleman AL (February 2017)."Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure".Cochrane Database of Systematic Reviews.2: CD012131.doi:10.1002/14651858.CD012131.pub2.PMC 5419424.PMID 28225198.
  16. Brouwer MC, McIntyre P, Prasad K, van de Beek D (September 2015)."Corticosteroids for acute bacterial meningitis".Cochrane Database of Systematic Reviews (9): CD004405.doi:10.1002/14651858.CD004405.pub5.PMC 6491272.PMID 26362566.
  17. Roila F, Ballatori E, Ruggeri B, DeAngelis V (May 2000)."Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy".The New England Journal of Medicine.342 (21):1554–9.doi:10.1056/NEJM200005253422102.PMID 10824073.
  18. Holte K, Kehlet H (November 2002). "Perioperative single-dose glucocorticoid administration: pathophysiologic effects and clinical implications".Journal of the American College of Surgeons.195 (5):694–712.doi:10.1016/s1072-7515(02)01491-6.PMID 12437261.
  19. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, et al. (November 2006). "Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study".Haematologica.91 (11):1498–505.PMID 17043025.Free to read
  20. 20.020.1"Dexamethasone and COVID-19".SPS - Specialist Pharmacy Service. Archived fromthe original on 22 July 2020. Retrieved2020-07-22.
  21. 21.021.1"Dexamethasone | Coronavirus Disease COVID-19".COVID-19 Treatment Guidelines. National Institutes of Health.Archived from the original on 7 July 2020. Retrieved12 July 2020.
  22. 22.022.1"COVID-19 Guideline, Part 1: Treatment and Management".Infectious Diseases Society of America.Archived from the original on 6 October 2020. Retrieved22 July 2020.Recommendation 4. Among hospitalized patients with severe* COVID-19, the IDSA guideline panel suggests glucocorticoids rather than no glucocorticoids. (Conditional recommendation, Moderate certainty of evidence)
    Remark: Dexamethasone 6 mg IV or PO for 10 days (or until discharge if earlier) or equivalent glucocorticoid dose may be substituted if dexamethasone unavailable. Equivalent total daily doses of alternative glucocorticoids to dexamethasone 6 mg daily are methylprednisolone 32 mg and prednisone 40 mg.
    Recommendation 5. Among hospitalized patients with COVID-19 without hypoxemia requiring supplemental oxygen, the IDSA guideline panel suggests against the use of glucocorticoids. (Conditional recommendation, Low certainty of evidence)
  23. Chrousos GP, Detera-Wadleigh SD, Karl M (December 1993)."Syndromes of glucocorticoid resistance"(PDF).Annals of Internal Medicine.119 (11):1113–24.doi:10.7326/0003-4819-119-11-199312010-00009.PMID 8239231.S2CID 26040431. Archived fromthe original(PDF) on 14 August 2017. Retrieved4 July 2020.
  24. Charmandari E, Kino T, Ichijo T, Chrousos GP (May 2008)."Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder".The Journal of Clinical Endocrinology and Metabolism.93 (5):1563–72.doi:10.1210/jc.2008-0040.PMC 2386273.PMID 18319312.
  25. Dan L. Longo, Anthony Fauci, Dennis Kasper, Stephen Hauser, J. Jerry Jameson and Joseph Loscalzo,Harrison's Principles of Internal MedicineArchived 1 August 2020 at theWayback Machine, 18th edition, p. 3055
  26. Bloom SL, Sheffield JS, McIntire DD, Leveno KJ (April 2001). "Antenatal dexamethasone and decreased birth weight".Obstetrics and Gynecology.97 (4):485–90.doi:10.1016/S0029-7844(00)01206-0.PMID 11275014.S2CID 33601749.
  27. Elton, Catherine (18 June 2010)."A Prenatal Treatment Raises Questions of Medical Ethics". Archived fromthe original on 31 August 2016 – via content.time.com.
  28. Hirvikoski T, Nordenström A, Wedell A, Ritzén M, Lajic S (June 2012)."Prenatal dexamethasone treatment of children at risk for congenital adrenal hyperplasia: the Swedish experience and standpoint".The Journal of Clinical Endocrinology and Metabolism.97 (6):1881–3.doi:10.1210/jc.2012-1222.PMID 22466333.
  29. Hirvikoski T, Nordenström A, Lindholm T, Lindblad F, Ritzén EM, Wedell A, Lajic S (February 2007)."Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone".The Journal of Clinical Endocrinology and Metabolism.92 (2):542–8.doi:10.1210/jc.2006-1340.PMID 17148562.
  30. Lajic S, Nordenström A, Hirvikoski T (2011)."Long-term outcome of prenatal dexamethasone treatment of 21-hydroxylase deficiency".Endocrine Development.20:96–105.doi:10.1159/000321228.ISBN 978-3-8055-9643-5.PMID 21164263.Archived from the original on 17 June 2020. Retrieved17 June 2020.
  31. Cymerman A, Rock PB (1994)."Medical Problems in High Mountain Environments. A Handbook for Medical Officers"(PDF). USARIEM-TN94-2. US Army Research Inst. of Environmental Medicine Thermal and Mountain Medicine Division Technical Report. Retrieved17 June 2020.{{cite journal}}:Cite journal requires|journal= (help)
  32. Eledrisi MS (April 2007). "First-line therapy for hypertension".Annals of Internal Medicine.146 (8): 615.doi:10.7326/0003-4819-146-8-200704170-00021.PMID 17438328.
  33. Grape S, Usmanova I, Kirkham KR, Albrecht E (April 2018)."Intravenous dexamethasone for prophylaxis of postoperative nausea and vomiting after administration of long-acting neuraxial opioids: a systematic review and meta-analysis".Anaesthesia.73 (4):480–489.doi:10.1111/anae.14166.PMID 29226971.
  34. Kovac AL (May 2006)."Meta-analysis of the use of rescue antiemetics following PONV prophylactic failure with 5-HT3 antagonist/dexamethasone versus single-agent therapies".The Annals of Pharmacotherapy.40 (5):873–87.doi:10.1345/aph.1G338.PMID 16670361.S2CID 32843029.Archived from the original on 18 June 2020. Retrieved17 June 2020.
  35. Polderman JA, Farhang-Razi V, Van Dieren S, Kranke P, DeVries JH, Hollmann MW, et al. (Cochrane Anaesthesia Group) (November 2018)."Adverse side effects of dexamethasone in surgical patients".Cochrane Database of Systematic Reviews.11: CD011940.doi:10.1002/14651858.CD011940.pub3.PMC 6426282.PMID 30480776.
  36. Sadeghirad B, Siemieniuk RA, Brignardello-Petersen R, Papola D, Lytvyn L, Vandvik PO, et al. (September 2017)."Corticosteroids for treatment of sore throat: systematic review and meta-analysis of randomised trials".BMJ.358: j3887.doi:10.1136/bmj.j3887.PMC 5605780.PMID 28931508.
  37. 37.037.1"Dexamethasone - WikEM".www.wikem.org.Archived from the original on 4 October 2017. Retrieved5 August 2020.
  38. 38.038.1"DEXAMETHASONE injectable - Essential drugs".medicalguidelines.msf.org.Archived from the original on 28 August 2021. Retrieved1 September 2020.
  39. 39.039.1"High Elevation Travel & Altitude Illness | CDC Yellow Book 2024".wwwnc.cdc.gov.Archived from the original on 22 June 2023. Retrieved10 July 2023.
  40. "Corticosteroids for COVID-19".www.who.int.Archived from the original on 11 October 2020. Retrieved3 September 2020.
  41. "Decadron, Dexamethasone Intensol (dexamethasone) dosing, indications, interactions, adverse effects, and more".Medscape Reference. WebMD.Archived from the original on 12 December 2013. Retrieved11 December 2013.
  42. 42.042.142.242.3"Product Information Dexamethsone (dexamethasone)"(PDF).TGA eBusiness Services. Aspen Pharmacare Australia Pty Ltd. 10 August 2010.Archived from the original on 28 January 2017. Retrieved11 December 2013. (Accept terms and conditions to open PDF, which doesn't work in archived version)
  43. "Product Information Dexmethsone Injection"(PDF).TGA eBusiness ServicesAspen Pharmacare Australia Pty Ltd. Aspen Pharmacare Australia Pty Ltd. 2 March 2011.Archived from the original on 29 January 2017. Retrieved11 December 2013. (Accept terms and conditions to open PDF, which doesn't work in archived version)
  44. "Dexamethasone tablet [ECR Pharmaceuticals]".DailyMed. ECR Pharmaceuticals. December 2010.Archived from the original on 13 December 2013. Retrieved11 December 2013.
  45. "Dexamethasone Tablet BP 2.0 mg – Summary of Product Characteristics (SPC)".electronic Medicines Compendium. Merck Sharp & Dohme Limited. 26 January 2018.Archived from the original on 17 June 2020. Retrieved17 June 2020.
  46. "Dexamethasone 4.0 mg/ml injection – Summary of Product Characteristics (SPC)".electronic Medicines Compendium. Merck Sharp & Dohme Limited. 4 December 2013. Archived fromthe original on 8 May 2015. Retrieved11 December 2013.
  47. Rosenberg, Aaron S. (28 January 2023)."From mechanism to resistance – changes in the use of dexamethasone in the treatment of multiple myeloma".Leukemia & Lymphoma.64 (2):283–291.doi:10.1080/10428194.2022.2136950.ISSN 1042-8194.
  48. De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, Nicolaides NC, Pavlaki AN, Maria Alexandra MA, Chrousos GP (2000)."Glucocorticoid Therapy and Adrenal Suppression".Endotext.PMID 25905379.Archived from the original on 1 July 2020. Retrieved17 June 2020.
  49. 49.049.1Khan MO, Park KK, Lee HJ (2005)."Antedrugs: an approach to safer drugs".Current Medicinal Chemistry.12 (19):2227–39.doi:10.2174/0929867054864840.PMID 16178782.Archived from the original on 18 June 2020. Retrieved17 June 2020.
  50. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, Brown JP, Cohen A, Kim H (August 2013)."A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy".Allergy, Asthma, and Clinical Immunology.9 (1): 30.doi:10.1186/1710-1492-9-30.PMC 3765115.PMID 23947590.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  51. Elks J (14 November 2014).The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 366–.ISBN 978-1-4757-2085-3.Archived from the original on 15 February 2017.
  52. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 310–.ISBN 978-3-88763-075-1.Archived from the original on 24 August 2017.
  53. Raynor JW, Minor W, Chruszcz M (2007). "Dexamethasone at 119 K".Acta Crystallographica Section E.63 (6):o2791 –o2793.doi:10.1107/S1600536807020806.
  54. Arth GE, Fried J, Johnston DBR, Hoff DR, Sarett HL, Silber RH, Stoerk HC, Winter CA (1958). "16-Methylated steroids. II. 16α-Methyl analogs of cortisone, a new group of anti-inflammatory steroids. 9α-Halo derivatives".Journal of the American Chemical Society.80 (12):3161–63.doi:10.1021/ja01545a063.
  55. Taub D, Hoffsommer RD, Slates HL, lWendler NL (1958). "16β-Methyl cortical steroids".Journal of the American Chemical Society.80 (16): 4435.doi:10.1021/ja01549a095.
  56. Valsler, Ben."Dexamethasone".Chemistry World.Archived from the original on 12 August 2020. Retrieved5 August 2020.
  57. "Dexamethasone in COVID-19"(PDF).www.gpni.co.uk. 16 June 2020.Archived(PDF) from the original on 17 June 2020. Retrieved18 June 2020.
  58. Mahase E (June 2020)."Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint".BMJ.369: m2512.doi:10.1136/bmj.m2512.PMID 32576548.
  59. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. (July 2020)."Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report".New England Journal of Medicine.doi:10.1056/NEJMoa2021436.PMID 32678530.Archived from the original on 18 July 2020. Retrieved18 July 2020.
  60. "Important to use dexamethasone only for serious COVID cases - WHO". 17 June 2020.Archived from the original on 17 June 2020. Retrieved18 June 2020.
  61. "WHO Director-General's opening remarks at the media briefing on COVID-19 - 22 June 2020".World Health Organization.Archived from the original on 12 September 2020. Retrieved26 June 2020.
  62. "Q&A: Dexamethasone and COVID-19".World Health Organization (WHO).Archived from the original on 11 October 2020. Retrieved12 July 2020.
  63. "EMA starts review of dexamethasone for treating adults with COVID-19 requiring respiratory support".European Medicines Agency (EMA) (Press release). 24 July 2020.Archived from the original on 30 January 2021. Retrieved27 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  64. "EMA to review results from study testing common steroid drug against COVID-19".Reuters. 24 July 2020.Archived from the original on 27 July 2020. Retrieved27 July 2020.
  65. Dummett, Mark (30 May 2010)."Bangladesh's dark brothel steroid secret".BBC News Online.Archived from the original on 22 February 2012.
  66. "Prohibited In-Competition: Glucocorticoids". World Anti-Doping Agency. Archived fromthe original on 16 July 2018. Retrieved16 July 2018.
  67. "Trichlormethiazide and Dexamethasone for veterinary use". Wedgewood Pharmacy.Archived from the original on 12 December 2007. Retrieved23 January 2008.

External links

External sites:
Identifiers:


Glucocorticoids
Natural
Synthetic
Antiglucocorticoids
Synthesis modifiers
Decongestants and other nasal preparations (R01)
Topical
Sympathomimetics, plain
Antiallergic agents,
excluding corticosteroids
Corticosteroids
Other nasal preparations
Combination products
Systemic use:
Sympathomimetics
GR
Agonists
Mixed
(SEGRMs)
Antagonists
Others
Angiopoietin
CNTF
EGF (ErbB)
EGF
(ErbB1/HER1)
ErbB2/HER2
ErbB3/HER3
ErbB4/HER4
FGF
FGFR1
FGFR2
FGFR3
FGFR4
Unsorted
HGF (c-Met)
IGF
IGF-1
IGF-2
Others
LNGF (p75NTR)
PDGF
RET (GFL)
GFRα1
GFRα2
GFRα3
GFRα4
Unsorted
SCF (c-Kit)
TGFβ
Trk
TrkA
TrkB
TrkC
VEGF
Others
CAR
PXR

Retrieved from "https://mdwiki.org/w/index.php?title=Dexamethasone&oldid=1458618"
Categories:

[8]ページ先頭

©2009-2025 Movatter.jp